Compare · NVO vs SEPN
NVO vs SEPN
Side-by-side comparison of Novo Nordisk A/S (NVO) and Septerna Inc. (SEPN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SEPN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 139.2x SEPN ($1.37B).
- Over the past year, NVO is down 46.1% and SEPN is up 196.4% - SEPN leads by 242.5 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 3 for SEPN).
- NVO has more recent analyst coverage (25 ratings vs 10 for SEPN).
- Company
- Novo Nordisk A/S
- Septerna Inc.
- Price
- $42.79+1.42%
- $30.44-1.87%
- Market cap
- $191.15B
- $1.37B
- 1M return
- -7.76%
- +29.20%
- 1Y return
- -46.07%
- +196.40%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 10
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest SEPN
- Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
- Chief People Officer Shaikhly Samira exercised 5,935 shares at a strike of $1.87 and sold $171,682 worth of shares (5,935 units at $28.93) as part of a pre-agreed trading plan (SEC Form 4)
- Chief People Officer Shaikhly Samira exercised 11,798 shares at a strike of $6.81 and sold $354,656 worth of shares (11,798 units at $30.06) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Septerna Inc.
- Septerna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
- Septerna to Present at Bank of America Securities Health Care Conference
- Stifel initiated coverage on Septerna with a new price target
- SEC Form DEFA14A filed by Septerna Inc.
- SEC Form DEF 14A filed by Septerna Inc.